Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at Xagrid har vist sig effektivt til at sænke blodpladetallet hos patienter med ET.
The Committee for Medicinal products for Human Use (CHMP) concluded that Xagrid had shown its effectiveness in lowering platelet counts in ET patients.